Boland, B; Yu, WH; Corti, O; Mollereau, B; Henriques, A; Bezard, E; Pastores, GM; ... Millan, MJ; + view all Boland, B; Yu, WH; Corti, O; Mollereau, B; Henriques, A; Bezard, E; Pastores, GM; Rubinsztein, DC; Nixon, RA; Duchen, MR; Mallucci, GR; Kroemer-, G; Levine, B; Eskelinen, E-L; Mochel, F; Spedding, M; Louis, C; Martin, OR; Millan, MJ; - view fewer (2018) Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nature Reviews Drug Discovery , 17 (9) pp. 660-688. 10.1038/nrd.2018.109.

Preview

Text NRDD revision .pdf - Accepted Version Download (2MB) | Preview

Abstract

Neurodegenerative disorders of ageing (NDAs) such as Alzheimer disease, Parkinson disease, frontotemporal dementia, Huntington disease and amyotrophic lateral sclerosis represent a major socio-economic challenge in view of their high prevalence yet poor treatment. They are often called 'proteinopathies' owing to the presence of misfolded and aggregated proteins that lose their physiological roles and acquire neurotoxic properties. One reason underlying the accumulation and spread of oligomeric forms of neurotoxic proteins is insufficient clearance by the autophagic–lysosomal network. Several other clearance pathways are also compromised in NDAs: chaperone-mediated autophagy, the ubiquitin–proteasome system, extracellular clearance by proteases and extrusion into the circulation via the blood–brain barrier and glymphatic system. This article focuses on emerging mechanisms for promoting the clearance of neurotoxic proteins, a strategy that may curtail the onset and slow the progression of NDAs.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item